Merus (NASDAQ:MRUS – Get Free Report) COO Peter B. Silverman sold 10,000 shares of the stock in a transaction dated Thursday, June 27th. The stock was sold at an average price of $60.00, for a total transaction of $600,000.00. The sale was disclosed in a document filed with the SEC, which is available at this link.
Merus Price Performance
MRUS traded down $1.03 on Friday, hitting $59.17. 1,163,148 shares of the stock were exchanged, compared to its average volume of 796,041. Merus has a 12 month low of $19.81 and a 12 month high of $61.61. The business has a 50-day moving average of $50.10 and a two-hundred day moving average of $42.52. The firm has a market capitalization of $3.47 billion, a price-to-earnings ratio of -21.73 and a beta of 1.10.
Merus (NASDAQ:MRUS – Get Free Report) last posted its earnings results on Wednesday, May 8th. The biotechnology company reported ($0.59) EPS for the quarter, topping analysts’ consensus estimates of ($0.83) by $0.24. The firm had revenue of $7.89 million during the quarter, compared to analysts’ expectations of $8.94 million. Merus had a negative net margin of 390.36% and a negative return on equity of 44.13%. Equities research analysts expect that Merus will post -3.1 earnings per share for the current fiscal year.
Institutional Trading of Merus
Analyst Ratings Changes
MRUS has been the topic of a number of research analyst reports. StockNews.com lowered shares of Merus from a “hold” rating to a “sell” rating in a report on Wednesday, May 22nd. BMO Capital Markets increased their price objective on shares of Merus from $84.00 to $91.00 and gave the stock an “outperform” rating in a report on Tuesday, June 4th. Guggenheim increased their price objective on shares of Merus from $57.00 to $93.00 and gave the stock a “buy” rating in a report on Tuesday, May 28th. Needham & Company LLC reaffirmed a “buy” rating and issued a $92.00 target price on shares of Merus in a research note on Friday. Finally, William Blair reaffirmed an “outperform” rating on shares of Merus in a research note on Monday, April 22nd. One investment analyst has rated the stock with a sell rating and twelve have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $80.90.
View Our Latest Report on Merus
About Merus
Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.
Featured Stories
- Five stocks we like better than Merus
- What does consumer price index measure?
- Qualcomm Stock: AI-Powered Growth Despite Volatility
- How to Invest in Blue Chip Stocks
- Salesforce Stock: Meeting Recap, AI Focus, and Forecast
- How to Invest in Biotech Stocks
- Is CAVA Overextended? A Closer Look at This High-Flying Stock
Receive News & Ratings for Merus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus and related companies with MarketBeat.com's FREE daily email newsletter.